Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate
Open Access
- 15 April 2020
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 37 (4) , 1-16
Abstract
Purpose: Sexual transmission of HIV has been clinically proven to be preventable with a once-daily oral tablet; however, missed doses dramatically increase the risk of HIV infection. Long-acting subcutaneous implants do not allow the user to miss a dose. A desirable long-acting drug-eluting implant can deliver a constant amount of drug, adjust the delivered dose, and be readily manufactured. We present a long-acting, subcutaneous implant design composed of tenofovir alafenamide hemifumarate (TAF) pellets loaded in a sealed polyether urethane tube for the prevention of HIV transmission. Methods: Implants were prepared with pressed drug pellets and extruded polyurethane tubing. In vitro release rate of implants using different pellet formulations, rate-controlling membranes, and geometries were measured. Results: Tenofovir alafenamide release appeared to be governed by a pseudo-steady state and followed a mass transport model of release from a cylindrical drug reservoir. Implant seal integrity was tested and confirmed using mechanical testing. The inclusion of sodium chloride in the pellet increased the release rate and reduced initial lag. The release was sustained for 100 days. Conclusions: The release rate of tenofovir alafenamide mechanistically varied with geometry and rate controlling membrane composition. The polyether urethane implant presented herein is modular and tunable to adjust the release rate and duration of the TAF release.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (UM1 AI120184)
This publication has 35 references indexed in Scilit:
- A 90-Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV ProphylaxisAntimicrobial Agents and Chemotherapy, 2012
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Modeling of diffusion controlled drug deliveryJournal of Controlled Release, 2012
- Effectiveness of Long-Acting Reversible ContraceptionNew England Journal of Medicine, 2012
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)European Psychiatry, 2009
- The impact of medication regimen factors on adherence to chronic treatment: a review of literatureJournal of Behavioral Medicine, 2008
- Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic TissueAntimicrobial Agents and Chemotherapy, 2005
- Contraceptive failure in the United StatesContraception, 2004
- A multicenter comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant® and Norplant®-IIContraception, 1997